rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
2004-4-6
|
pubmed:abstractText |
Neutropenic fever is one of the most serious adverse effects of cancer chemotherapy. Neutropenia may cause a life-threatening bacterial infection. Therefore, febrile neutropenic inpatients are empirically treated with intravenous broad-spectrum antibiotics. Recently, several studies have suggested the presence of low-risk groups among febrile neutropenic patients.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0368-2811
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
69-73
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15067098-Administration, Oral,
pubmed-meshheading:15067098-Aged,
pubmed-meshheading:15067098-Amoxicillin-Potassium Clavulanate Combination,
pubmed-meshheading:15067098-Anti-Infective Agents,
pubmed-meshheading:15067098-Ceftazidime,
pubmed-meshheading:15067098-Ciprofloxacin,
pubmed-meshheading:15067098-Drug Therapy, Combination,
pubmed-meshheading:15067098-Female,
pubmed-meshheading:15067098-Fever,
pubmed-meshheading:15067098-Humans,
pubmed-meshheading:15067098-Infusions, Intravenous,
pubmed-meshheading:15067098-Lung Neoplasms,
pubmed-meshheading:15067098-Male,
pubmed-meshheading:15067098-Middle Aged,
pubmed-meshheading:15067098-Neutropenia,
pubmed-meshheading:15067098-Prospective Studies,
pubmed-meshheading:15067098-Treatment Outcome
|
pubmed:year |
2004
|
pubmed:articleTitle |
Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer.
|
pubmed:affiliation |
Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. siniho@east.ncc.go.jp
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|